Previous 10 | Next 10 |
Positive final results from the vurolenatide Phase 2 VIBRANT study in short bowel syndrome (SBS) reaffirmed the efficacy and safety of vurolenatide and determined the Phase 3 dose and regimen Clinical plans and activities are underway including site and patient recruitment to facilitat...
Preclinical data investigated the use of glucose-dependent insulinotropic polypeptide (GIP) monoclonal antibodies (mAbs) to prevent and treat obesity in animal models Poster granted Outstanding Research Award 9 Meters is developing NM-136, an anti-GIP humanized mAb, for targeted o...
RALEIGH, NC / ACCESSWIRE / October 18, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced two poster presentations at the American College of Gastroenterology (ACG) 2022 Annual...
Clinical-stage company 9 Meters Biopharma ( NASDAQ: NMTR ) is set to execute a 1-for-20 reverse stock split, effective Oct. 17 5:00 p.m. ET. The company will begin trading on a split-adjusted basis from Oct. 18 under the existing ticker symbol NMTR. The move, whic...
RALEIGH, NC / ACCESSWIRE / October 17, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that it will be executing a reverse stock split of its outstanding shares of com...
A North Carolina-based %Biotech company is seeing some premarket action on Tuesday after the company announced the final results from the Phase 2 VIBRANT study of vurolenatide in %ShortBowelSyndrome (SBS) and the outcome of its End-ofPhase 2 meeting with the FDA, according to the ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Eric Urquhart/Shutterstock.com We’re starting off the day with a look at the biggest pre-market stock movers for Tuesday morning! Moving shares this morning is a reverse stock split, clinical trial re...
9 Meters Biopharma, Inc. ( NASDAQ: NMTR ), a company focused on rare digestive diseases, added ~24% pre-market Tuesday in reaction to final Phase 2 data for vurolenatide, a candidate for short bowel syndrome (SBS). A long-acting GLP-1 receptor agonist, vurolenatide, is d...
Vurolenatide 50 mg every two weeks (Q2W) dosing arm demonstrated a 30% reduction over six weeks in the primary endpoint of the Phase 2 study, mean reduction in total stool output (TSO), compared with a 32% increase for placebo - for a mean relative reduction of 62% Based on End-of-Phas...
RALEIGH, NC / ACCESSWIRE / September 6, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that John Temperato, President & Chief Executive Officer of 9 Meters, will ...
News, Short Squeeze, Breakout and More Instantly...
9 Meters Biopharma Inc. Company Name:
NMTR Stock Symbol:
NASDAQ Market:
RALEIGH, NC / ACCESSWIRE / May 30, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced that the Board of Directors has accepted the resignation of John Temperato as President ...
RALEIGH, NC / ACCESSWIRE / May 15, 2023 / 9 Meters Biopharma, Inc. (Nasdaq:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided a business update and announced financial results for the first quarter ended March 31, 2...
RALEIGH, NC / ACCESSWIRE / April 5, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced receipt of a written response from the U.S. Food and Drug Administration (FDA) on the r...